60,100 results match your criteria Myeloma


[Indicators of kidney damage in patients with multiple myeloma in the process of chemotherapeutic treatment.]

Klin Lab Diagn 2018 ;63(12):741-749

Rostov Research Institute of Oncology, Rostov-on-Don, Russia.

The purpose was to study the level of acute kidney injury markers cystatin C, KIM-1, IL-18, NGAL and L-FABR in the blood and urine of patients with the initially identified secreting multiple myeloma (MM) before and during chemotherapeutic treatment. The content of renal markers was examined by ELISA using commercial kits. The study included 23 patients with MM who received 6-8 21-day cycles of chemotherapy (CT) according to the VCD scheme. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18821/0869-2084-2018-63-12-741-749DOI Listing
January 2018

The pharmacologic management of multiple myeloma in older adults.

Expert Opin Pharmacother 2019 Feb 20:1-16. Epub 2019 Feb 20.

d Department of Medicine, Division of Hematology and Oncology , Case Western Reserve University , Cleveland , OH , USA.

Introduction: Multiple myeloma is a disease predominately affecting older adults. Pivotal to treating older adults is understanding their physiologic differences compared to younger subjects and how the complexity of therapies has an impact upon this patient population. Areas covered: Herein, the authors address the efficacy of chemotherapy regimens, decision-making for older adults, chemotherapy-associated toxicity and the approach to management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1577822DOI Listing
February 2019

Antitumor Activity of Asiaticoside Against Multiple Myeloma Drug-Resistant Cancer Cells Is Mediated by Autophagy Induction, Activation of Effector Caspases, and Inhibition of Cell Migration, Invasion, and STAT-3 Signaling Pathway.

Med Sci Monit 2019 Feb 20;25:1355-1361. Epub 2019 Feb 20.

Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China (mainland).

BACKGROUND Accumulating evidence suggests that plant-derived molecules may prove extremely beneficial in the development of chemotherapy for deadly cancer types. Multiple myeloma is a rare and incurable type of cancers. Very little research has been directed towards the development of chemotherapy for the management of multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.913397DOI Listing
February 2019

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Neoplasma 2019 Feb 20. Epub 2019 Feb 20.

Lenalidomide (LEN) is an immunomodulator with clinical activity against myeloma cells. Based on the pivotal phase 3 trials MM-009 and MM010, the combination of lenalidomide and dexamethasone(DEX) was approved for patients with multiple myeloma who received at least one prior therapy. Here, we evaluated LEN/DEX therapy in whole population and subsequently in selected sub-groups of patients with relapsed/refractory multiple myeloma followed in the Monoclonal Gammopathy Registry of the Czech Myeloma Group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/neo_2018_180824N644DOI Listing
February 2019

Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.

Bone Marrow Transplant 2019 Feb 19. Epub 2019 Feb 19.

Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.

Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007-2014 (287 were aged ≥65 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0478-4DOI Listing
February 2019

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing.

Blood Cancer J 2019 Feb 19;9(3):21. Epub 2019 Feb 19.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Microarray analysis of the multiple myeloma (MM) miRNome has unraveled the differential expression of miRNAs in cytogenetic subgroups, their involvement in the tumor biology and their effectiveness in prognostic models. Herein, the small RNA transcriptional landscape in MM has been investigated exploiting the possibilities offered by small RNA-seq, including accurate quantification of known mature species, discovery and characterization of isomiRs, and miRNA-offset RNAs (moRNAs). Matched small RNA-seq and miRNA GeneChip microarray expression profiles were obtained in a representative panel of 30 primary MM tumors, fully characterized for genomic aberrations and mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0184-xDOI Listing
February 2019

Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.

Proc Natl Acad Sci U S A 2019 Feb 19. Epub 2019 Feb 19.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

Multiple myeloma (MM) is a B cell malignancy for which new treatments are urgently needed. The B cell maturation antigen (BCMA) is a lineage-restricted differentiation protein highly expressed on myeloma. Recombinant immunotoxins (RITs) are proteins composed of the Fv or Fab portion of an antibody fused to a bacterial toxin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1821733116DOI Listing
February 2019

The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.

Biosci Rep 2019 Feb 19. Epub 2019 Feb 19.

Blood Diseases Institute, Xuzhou Medical University, xuzhou, China

Multiple myeloma (MM) is a hematological malignancy of plasma cells that produce a monoclonal immunoglobulin protein. Despite significant advances in the treatment of MM, challenges such as resistance to therapy remain. Currently, inhibition of histone deacetylases (HDACs) is emerging as a potential method for treating cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BSR20181916DOI Listing
February 2019

A role for IL-34 in osteolytic disease of multiple myeloma.

Blood Adv 2019 Feb;3(4):541-551

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Multiple myeloma (MM) is a hematological malignancy that grows in multiple sites of the axial skeleton and causes debilitating osteolytic disease. Interleukin-34 (IL-34) is a newly discovered cytokine that acts as a ligand of colony-stimulating factor-1 (CSF-1) receptor and can replace CSF-1 for osteoclast differentiation. In this study, we identify IL-34 as an osteoclastogenic cytokine that accelerates osteolytic disease in MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018020008DOI Listing
February 2019

An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers.

Expert Rev Mol Diagn 2019 Feb 20. Epub 2019 Feb 20.

b Hematology and Stem Cell Transplantation Unit, IRCCS-Referral Cancer Center of Basilicata (CROB) , Via Padre Pio,1, Rionero in Vulture ( PZ ), Italy.

Introduction: Multiple myeloma (MM) is characterized by a clonal proliferation of neoplastic plasma cells (PCs) in bone marrow (BM) and the interplay between MM PCs and the BM microenvironment, which plays a relevant role in its pathogenesis. In this important cross-talk, extracellular vesicles (EVs) are active. EVs, including small and medium/large EVs, are lipid bi-layer particles released in circulation by normal and neoplastic cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2019.1583103DOI Listing
February 2019

Long Non Coding RNA H19: A New Player in Hypoxia-Induced Multiple Myeloma Cell Dissemination.

Int J Mol Sci 2019 Feb 13;20(4). Epub 2019 Feb 13.

Department of BioMedicine, Neurosciences and Advanced Diagnostics (Bi.N.D), Via Divisi 83, 90133 Palermo, Italy.

The long non-coding RNA H19 (lncH19) is broadly transcribed in the first stage of development and silenced in most cells of an adult organism; it appears again in several tumors where, through different molecular mediators, promotes cell proliferation, motility and metastases. LncH19 has been associated with hypoxia-inducible factor 1-alpha (HIF-1α) activation and, in some tumors, it has proved to be necessary and required to sustain hypoxic responses. Here we propose to investigate a putative role for the lncH19 in hypoxia induced multiple myeloma (MM) progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040801DOI Listing
February 2019

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Cancers (Basel) 2019 Feb 18;11(2). Epub 2019 Feb 18.

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Aberrant expression of microRNAs (miRNAs) has been associated to the pathogenesis of multiple myeloma (MM). While miR-155 is considered a therapeutic target in several malignancies, its role in MM is still unclear. The analysis of miR-155 expression indicates its down-regulation in MM patient-derived as compared to healthy plasma cells, thus pointing to a tumor suppressor role in this malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020236DOI Listing
February 2019

Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development.

Int J Mol Sci 2019 Feb 15;20(4). Epub 2019 Feb 15.

Department of Microbiological and Nanobiomedical Engineering, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.

There is a rising number of evidence indicating the increased risk of cancer development in association with congenital metabolic errors. Although these diseases represent disorders of individual genes, they lead to the disruption of metabolic pathways resulting in metabolite accumulation or their deficiency. Gaucher disease (GD) is an autosomal recessive sphingolipidosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040843DOI Listing
February 2019

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Methods Mol Biol 2019 ;1956:199-228

Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.

Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell non-Hodgkin lymphomas (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. MRD diagnostics performed by real-time quantitative PCR (RQ-PCR) is still the gold standard and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). Alternatively, droplet digital PCR (ddPCR) can be used for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma with comparable sensitivity, accuracy, and reproducibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_9DOI Listing
January 2019

Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.

Methods Mol Biol 2019 ;1956:157-197

Division of Internal Medicine, Medical Clinic III-Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.

The quantification of submicroscopic minimal residual disease (MRD) after therapy proved to have independent prognostic significance in many mature B-cell malignancies. With the advent of routine benchtop cytometers capable of simultaneously analyzing ≥4 colors and with improved standardization, flow cytometry has become the method of choice for MRD assessments in some lymphoma entities. Herein we describe general aspects of flow cytometric standardization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_8DOI Listing
January 2019

Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.

Int J Hematol 2019 Feb 18. Epub 2019 Feb 18.

Department of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan.

We sought to determine the efficacy of a new, inexpensive, single-tube 8-color multiparameter flow cytometry (MFC) method (SRL-Flow), which is based on the EuroFlow next-generation flow (NGF) (tube 2 only), to assess minimal residual disease (MRD)-negative status. MRD-negative status is considered a treatment milestone in multiple myeloma (MM). We used 45 bone marrow samples from patients with MM, including 11 cases treated with anti-CD38 monoclonal antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02615-zDOI Listing
February 2019

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.

Leuk Lymphoma 2019 Feb 19:1-12. Epub 2019 Feb 19.

c Cabrini Health , Australia and Monash University , Melbourne , Australia.

Efficacy and safety of bortezomib-based consolidation following ASCT were investigated in newly diagnosed multiple myeloma patients from Australia, Korea, and China. Patients received three cycles of bortezomib-cyclophosphamide-dexamethasone induction followed by high-dose therapy/ASCT, then were randomized (1:1) to consolidation with TP (thalidomide 100 mg/d for ≤12 months/until disease progression; prednisolone 50 mg on alternate days indefinitely/until disease progression; n = 100) or VTP (subcutaneous bortezomib 1.3 mg/m every 2 weeks for 32 weeks, plus TP; n = 103). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1579322DOI Listing
February 2019

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.

Authors:
Erik De Clercq

Antivir Chem Chemother 2019 Jan-Dec;27:2040206619829382

Rega Institute for Medical Research, Leuven, Belgium.

AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF-1 (also named CXCL12), it also mobilized the CD34stem cells from the bone marrow into the peripheral blood stream. In December 2008, AMD3100 was formally approved by the US FDA for autologous transplantation in patients with Non-Hodgkin's Lymphoma or multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040206619829382DOI Listing
February 2019

Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells.

Bone 2019 Feb 15;122:82-92. Epub 2019 Feb 15.

Department of Oncology and Metabolism, Medical School, University of Sheffield, UK. Electronic address:

Multiple myeloma (MM) is characterised by destructive lytic bone disease, caused by induction of bone resorption and impaired bone formation. Our understanding of the molecular mechanisms responsible for osteoblast suppression, are limited. Using the 5T2MM murine model of MM we have previously shown that suppression of the activity of a known inhibitor of bone formation Dikkopf-1 (Dkk1) prevents the development of lytic bone disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2019.02.012DOI Listing
February 2019

Clinical significance of trabecular bone score for prediction of pathologic fracture risk in patients with multiple myeloma.

Osteoporos Sarcopenia 2018 Jun 11;4(2):73-76. Epub 2018 Jun 11.

Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.

Objectives: Osteolytic bone lesions are common complications in multiple myeloma (MM), and can have an impact on quality of life due to the risk of fractures. Trabecular bone score (TBS) is a novel texture index derived from dual energy x-ray absorptiometry (DXA) of lumbar spine (LS) images that provides information about bone microarchitecture. The aim of this study was to evaluate whether TBS is useful in predicting bone fractures in MM patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.afos.2018.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362949PMC

Monoclonal Gammopathy of Undetermined Significance-associated Scleromyxoedema.

Indian Dermatol Online J 2019 Jan-Feb;10(1):54-57

Department of Dermatology, Smt. N.H.L Medical College, Ahmedabad, Gujarat, India.

Scleromyxoedema is a rare generalized cutaneous mucinosis, which in absence of thyroid disease, occurs almost invariably in patients with monoclonal gammopathies. A 54-year-old female patient presented with complaint of tightening of skin on the extremities, abdomen, forehead, gradually progressive since 1 year, episodes of generalized tonic-clonic convulsions, and acute psychosis since 5 days. Cutaneous examination revealed nonpitting edema over the face and sclerodermoid changes over extremities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_138_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362733PMC
February 2019

Plasma Cell Myeloma Masquerading as Scleromyxedema.

Indian Dermatol Online J 2019 Jan-Feb;10(1):50-53

Department of General Medicine, St. John's Medical College, Bengaluru, Karnataka, India.

Scleromyxedema is a rare progressive cutaneous mucinosis of unknown etiology with equal prevalence in both men and women. It is usually associated with monoclonal gammopathy in most of the cases. Various treatment modalities have been tried for scleromyxedema including steroids, intravenous immunoglobulin (IVIg), autologous hematopoietic stem cell transplantation, and melphalan, but none has proved to be fully effective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_135_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362738PMC
February 2019

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of .

Oncotarget 2019 Jan 22;10(7):732-737. Epub 2019 Jan 22.

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Hyperhaploid multiple myeloma is a rare numerical aberration group defined by a range of 24-34 chromosomes, which is associated with a poor prognosis with a 5-year survival rate of 23%. Hyperhaploid patient samples (n=8) were sequenced and copy number and mutations identified. Samples had a median of 13 monosomies (range 12-14), which in general were those not associated with trisomies in hyperdiploid samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26589DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366829PMC
January 2019

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.

Clin Ther 2019 Feb 14. Epub 2019 Feb 14.

US Oncology Research/Rocky Mountain Cancer Centers, Denver, CO, USA.

Purpose: Multiple new regimens are available for the treatment of relapsed/refractory multiple myeloma (RRMM). In this context, it is increasingly important to understand the differential costs of regimens used to treat RRMM.

Methods: A treatment journey for RRMM during a 12-month period of therapy was developed to reflect real-world clinical practice based on current treatment guidelines and input from hematologists/oncologists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2019.01.009DOI Listing
February 2019

Evaluating the role of Tregs in the progression of multiple myeloma.

Leuk Lymphoma 2019 Feb 18:1-9. Epub 2019 Feb 18.

c Leukemia/BMT Program of BC, British Columbia Cancer Agency , University of British Columbia , Vancouver , BC , Canada.

The role of regulatory T-cells (Treg) and Th17 cells in the progression of multiple myeloma has been unclear. There are conflicting reports of the Treg and Th17 frequency being increased, decreased, and unchanged as compared with controls. In this study, we sought to characterize the T-cell subsets including Treg function in both blood and marrow compartments of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1579324DOI Listing
February 2019

Lifetime exposure to rubber dusts, fumes and N-nitrosamines and cancer mortality in a cohort of British rubber workers with 49 years follow-up.

Occup Environ Med 2019 Feb 16. Epub 2019 Feb 16.

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Objectives: To quantitatively evaluate exposure-response associations between occupational exposures to rubber dust, fumes and N-nitrosamines and cancer mortality in the UK rubber industry.

Methods: Competing risk survival analyses were used to examine cancer mortality risk in a cohort of 36 441 males aged 35+ years employed in the British rubber industry in 1967, followed up to 2015 (94% mortality). Exposure measurements are based on a population-specific quantitative job-exposure matrix for rubber dust, rubber fumes and N-nitrosamines from the EU-EXASRUB project. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/oemed-2018-105181DOI Listing
February 2019

Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).

Clin Lymphoma Myeloma Leuk 2019 Jan 19. Epub 2019 Jan 19.

Stem Cell and Cancer Institute, Jakarta, Indonesia; Kalbe Genomics Laboratory, Jakarta, Indonesia.

Background: Defining the presence of BCR-ABL transcript in suspected myeloproliferative neoplasm is essential in establishing chronic myeloid leukemia. In the absence of BCR-ABL, the conventional diagnostic algorithm recommends JAK2 V617F mutation testing to support diagnosis of other MPN diseases such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In certain cases of thrombocythemia, simultaneous upfront testing of both BCR-ABL and JAK2 may be desirable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.005DOI Listing
January 2019
1 Read

Clinical intelligence: New machine learning techniques for predicting clinical drug response.

Comput Biol Med 2019 Jan 3. Epub 2019 Jan 3.

New Jersey Institute of Technology, Bioinformatics Program and Department of Computer Science, Newark, NJ, 07102-1982, USA. Electronic address:

Predicting the response, or sensitivity, of a clinical drug to a specific cancer type is an important research problem. By predicting the clinical drug response correctly, clinicians are able to understand patient-to-patient differences in drug sensitivity outcomes, which in turn results in lesser time spent and lower cost associated with identifying effective drug candidates. Although technological advances in high-throughput drug screening in cells led to the generation of a substantial amount of relevant data, the analysis of such data would be a challenging task. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiomed.2018.12.017DOI Listing
January 2019

Alkali-soluble pectin suppresses IgE production in human myeloma cell line in vitro.

Cytotechnology 2019 Feb 15. Epub 2019 Feb 15.

Department of Creative Engineering, National Institute of Technology, Kitakyushu College, 5-20-1 Shii, Kokuraminami-ku, Kitakyushu, Fukuoka, 802-0985, Japan.

We found that strawberry (Fragaria x ananassa) extract has an IgE production suppressive activity and its oral administration improved skin manifestation in atopic dermatitis model mice. In present study, we identified an active substance using the IgE-producing human myeloma cell line U266. Gel filtration experiment indicated that the IgE suppressor was more than 6 kDa in molecular size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10616-019-00306-5DOI Listing
February 2019

F-FDG PET/CT in multiple myeloma: critical insights and future directions.

Eur J Nucl Med Mol Imaging 2019 Feb 15. Epub 2019 Feb 15.

CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04279-7DOI Listing
February 2019
1 Read

Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.

Leukemia 2019 Feb 15. Epub 2019 Feb 15.

Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Aberrant activation of Wnt/β-catenin signaling plays a central role in the pathogenesis of a wide variety of malignancies and is typically caused by mutations in core Wnt pathway components driving constitutive, ligand-independent signaling. In multiple myelomas (MMs), however, these pathway intrinsic mutations are rare despite the fact that most tumors display aberrant Wnt pathway activity. Recent studies indicate that this activation is caused by genetic and epigenetic lesions of Wnt regulatory components, sensitizing MM cells to autocrine Wnt ligands and paracrine Wnts emanating from the bone marrow niche. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0404-1DOI Listing
February 2019

Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103 dendritic cell differentiation.

Nat Commun 2019 Feb 15;10(1):862. Epub 2019 Feb 15.

Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

The original version of this Article contained errors in the author affiliations. Qingnan Zhao, Xueqing Xia, Longfei Huo and Shulin Li were incorrectly associated with Beijing Institute for Brain Disorders, 100069, Beijing, China.This has now been corrected in both the PDF and HTML versions of the Article. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-019-08770-5
Publisher Site
http://dx.doi.org/10.1038/s41467-019-08770-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377651PMC
February 2019
1 Read
10.742 Impact Factor

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.

Clin Lymphoma Myeloma Leuk 2018 Dec 21. Epub 2018 Dec 21.

MDS Unit, AOU Careggi, University of Florence, Florence, Italy.

Background: In the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).

Patients And Methods: This analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.012DOI Listing
December 2018
1 Read

Adding Oral Pioglitazone to Standard Induction Chemotherapy of Acute Myeloid Leukemia: A Randomized Clinical Trial.

Clin Lymphoma Myeloma Leuk 2019 Jan 19. Epub 2019 Jan 19.

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Background: The hypothesis of an effect by thiazolidinedione on leukemia cells was proposed 2 decades ago, but there is little clinical evidence regarding its efficacy. We evaluated the safety and efficacy of adding pioglitazone to standard induction chemotherapy in patients with acute myeloid leukemia (AML).

Patients And Methods: In this randomized clinical trial, newly diagnosed AML patients were randomized to 1 of 2 groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.006DOI Listing
January 2019

Regions of homozygosity as risk factors for multiple myeloma.

Ann Hum Genet 2019 Feb 15. Epub 2019 Feb 15.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Genomic regions of homozygosity (ROH), detectable in outbred populations, have been implicated as determinants of inherited risk. To examine whether ROH is associated with risk of multiple myeloma (MM), we performed whole-genome homozygosity analysis using single-nucleotide polymorphism genotype data from 2,282 MM cases and 5,197 controls, with replication in an additional 878 MM cases and 7,083 controls. Globally, the distribution of ROH between cases and controls was not significantly different. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ahg.12304DOI Listing
February 2019

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Br J Haematol 2019 Feb 15. Epub 2019 Feb 15.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high-risk phenotype among standard-risk patients. Fifty-six percent of all patients presented with standard-risk disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15800DOI Listing
February 2019
2 Reads

SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.

Am J Surg Pathol 2019 Feb 12. Epub 2019 Feb 12.

Departments of Hematopathology.

Studies have suggested that SOX11 expression has prognostic implications in patients with mantle cell lymphoma (MCL), but the data are controversial. In this study, we describe the clinicopathologic and prognostic features of 75 patients with SOX11-negative MCL. Compared with patients with SOX11-positive MCL, SOX11-negative MCL patients more frequently had leukemic non-nodal disease (21% vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001233DOI Listing
February 2019
1 Read

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study.

South Asian J Cancer 2019 Jan-Mar;8(1):60-64

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Introduction: Plasma cells (PCs) have conventionally been counted on the bone marrow aspirate, and small focal involvement may be missed even on bone marrow biopsy sections.

Material And Methods: We aimed to study the role of CD138, CD56, anti-κ, and anti-λ immunohistochemistry (IHC) to separate PC myeloma from reactive plasmacytosis and to study the utility of these in cases suspected as myelomas and lacking >10% PCs on bone marrow aspirate. The study comprised 35 diagnosed myelomas, 20 reactive plasmacytosis, and 19 M-band positive suspected myelomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_64_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348785PMC
February 2019

Upregulation of lncRNA NR_046683 Serves as a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma.

Front Pharmacol 2019 31;10:45. Epub 2019 Jan 31.

Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, China.

To investigate the prognostic value of lncRNA NR_046683 in multiple myeloma (MM). High-throughput lncRNA array was combined with bioinformatics techniques to screen differentially expressed lncRNA in MM. qRT-PCR was adopted to determine the expression of target lncRNAs in MM patients and controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365438PMC
January 2019
1 Read

Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.

J Am Soc Nephrol 2019 Feb 14. Epub 2019 Feb 14.

School of Public Health, University of Sydney, Sydney, Australia.

Patients with ESRD have a substantially increased cancer risk, but few studies have examined the patterns of cancer mortality along a patient's journey from dialysis to transplantation.

Methods: We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry. Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on dialysis and patients with transplants versus the general population (overall and by age, sex, year, and site); we also performed a subgroup analysis excluding patients with preexisting cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2018090906DOI Listing
February 2019
2 Reads
9.343 Impact Factor

miR-221/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma.

Mol Ther 2019 Jan 24. Epub 2019 Jan 24.

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China. Electronic address:

Inherent or acquired resistance to chemotherapeutic drugs is still an obstacle for the treatment of multiple myeloma (MM). MicroRNA dysregulation is related to the development of chemoresistance in cancers. However, its role in chemoresistance of MM is largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2019.01.012DOI Listing
January 2019
1 Read

Epidemiology of Plasma Cell Leukemia in the Czech Republic.

Klin Onkol 2019 ;32(1):47-51

Background: Plasma cell leukemia (PCL) is a rare but most aggressive form of monoclonal gammopathies. PCL is characterized by the presence of clonal plasma cells in peripheral blood. There are two forms of PCL - primary which presents de novo in patients with no evidence of previous multiple myeloma and secondary which is a leukemic transformation of relapsed or refractory dis-ease in patients with previously recognized multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14735/amko2019DOI Listing
January 2019
1 Read

Plasma Cell Leukemia -  the Forgotten Dis-ease.

Klin Onkol 2019 ;32(1):40-46

Background: Plasma cell leukemia (PCL) is a rare dis-ease and possibly the most aggressive form of monoclonal gammopathy. It is classified into two forms -  primary PCL that occurs without a previously identifiable multiple myeloma stage, and secondary PCL that develops from previously dia-gnosed multiple myeloma. These two forms have different cytogenetic and molecular profiles, but both forms have an aggressive clinical course. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

Actinomyces Orbital Osteomyelitis in the Setting of Multiple Myeloma and Bisphosphonate-Related Osteonecrosis.

J Neuroophthalmol 2019 Mar;39(1):120-121

Department of Ophthalmology, Saint Louis University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNO.0000000000000729DOI Listing
March 2019
1 Read

The experiences and needs of primary family caregivers of patients with multiple myeloma: A qualitative analysis.

Palliat Med 2019 Feb 14:269216319830017. Epub 2019 Feb 14.

6 Department of Nursing, Escola Universitària d'Infermeria Gimbernat, Barcelona, Spain.

Background:: Family caregivers play a key role in the lives of patients with multiple myeloma. However, very little is known about the impact that the disease (its diagnosis, course and prognosis) has on the main family caregiver.

Aim:: To achieve a deeper understanding of the lived experience of individuals who are the primary caregiver of a relative with multiple myeloma and to shed light on their needs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269216319830017DOI Listing
February 2019
1 Read